New hormone therapy for advanced prostate cancer
Part of Kidney & urinary clinical trials.
This study tests a new injectable medication (teverelix DP) that lowers a hormone called testosterone to help control advanced prostate cancer. It is for men who haven't had hormone therapy before and who are otherwise relatively healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 18 and 85 years old
- You have advanced prostate cancer that has not been treated with hormone therapy before
- You agree to use effective birth control (or be abstinent) during the study and for 3 months after
- You cannot have serious liver, kidney, or heart problems, or have had a heart attack or stroke recently
- You cannot have had another cancer (except certain skin cancers or very early cancers) in the last 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
This study tests a medication called teverelix that may help shrink an enlarged prostate and improve urinary function after a sudden inability to urinate. It aims to reduce the chances of needing surgery or a catheter again.
This trial checks if a new version of the prostate cancer drug triprerelin works the same as the current one. It may be an option for men with prostate cancer who need hormone therapy.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.